DiaMedica Therapeutics, Inc.

( )
DMAC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 3.15%454.600.0%$6127.57m
BNTXBioNTech SE 4.05%352.990.0%$1059.79m
NVAXNovavax, Inc. 10.90%257.3079.4%$994.94m
SNSSSunesis Pharmaceuticals, Inc. 2.00%8.690.7%$607.46m
AMGNAmgen, Inc. 0.66%215.051.4%$556.80m
GILDGilead Sciences, Inc. 0.43%71.691.0%$457.92m
REGNRegeneron Pharmaceuticals, Inc. -0.09%646.512.7%$422.03m
TECHBio-Techne Corp. 0.73%536.904.5%$370.97m
ILMNIllumina, Inc. -0.32%433.203.5%$350.21m
BIIBBiogen, Inc. 1.34%293.201.7%$310.59m
VRTXVertex Pharmaceuticals, Inc. 0.45%185.091.9%$247.51m
ISEEIVERIC bio, Inc. 1.44%16.230.0%$190.62m
LIFEaTyr Pharma, Inc. 8.33%12.482.1%$188.70m
DVAXDynavax Technologies Corp. 4.31%19.605.7%$160.10m
BGNEBeiGene Ltd. -0.71%385.421.3%$145.35m

Company Profile

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.